Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy

Current Cardiology Reports

Volumn 3, Issue 2, 2001, Pages 160-166

  Seggewiss, Hubert ^a  

^a Leopoldina Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

FOLLOW UP; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; FOLLOW-UP STUDIES; HUMANS;

EID: 0035289741     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0044-7     Document Type: Article

References (38)

1. Niimura H, Bachinski LL, Sangwatanaroj S, et al.: Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
2. McKenna WJ, Coccolo F, Elliot PM: Genes and disease expression in hypertrophic cardiomyopathy. Lancet 1998, 352:1162-1163.
3. Wigle ED, Rakowski H, Kimball BP, et al.: Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995, 92:1680-1692.
4. Klues HG, Maron BJ, Dollar AL, et al.: Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85:1651-1660.
5. Liberthson RR: Sudden death from cardiac causes in children and young adults. New Engl J Med 1996, 334:1039-1044.
6. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775-785.
7. Maron BJ: Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment? J Am Coll Cardiol 1996, 27:431-432.
8. Schulte HD, Gramsch-Zabel H, Schwartzkopff B: Hypertrophe obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wschr 1995, 125:1940-1949 (in German).
9. Robbins RC, Stinson EB, Daily PO: Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996, 111:586-594.
10. Heric B, Lytle BW, Miller DP, et al.: Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg 1995, 110:195-208.
11. Schoendube FA, Klues HG, Reith S, et al.: Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995, 92(suppl II):122-127.
12. Maron BJ, Nishimura RA, Danielson GK: Pitfalls in clinical recognition and a novel operative approach for hypertrophic obstructive cardiomyopathy with severe obstruction due to anamalous papillary muscle. Circulation 1998, 98:2505-2508.
13. Kuhn H, Gietzen F, Leuner C, et al.: Induction of subaortic ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997, 18:846-851.
14. Sigwart U: Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211-214.
15. Seggewiss H, Gleichmann U, Faber L, et al.: Percutaneous transluminal septal myocardardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998, 31:252-258.
16. Faber L, Seggewiss H, Gleichmann U: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute and 3-months follow-up results with respect to myocardial contrast echocardiography. Circulation 1998, 98:2415-2421.
17. Faber L, Seggewiss H, Fassbender D, et al.: Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography. J Interv Cardiol 1998, 11:443-448.
18. Faber L, Seggewiss H, Ziemssen P, Gleichmann U: Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 1999, 47:462-466.
19. Ruzyllo W, Chojnowska L, Demkow M, et al.: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000, 21:770-777.
20. Maron BJ, Casey SA, Poliac LC, et al.: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999, 281:650-655.
21. Seggewiss H, Faber L, Meyners W, et al.: Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report. Cathet Cardiovasc Diagn 1998, 44:65-69.
22. Gleichmann U, Seggewiss H, Faber L, et al.: Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Dtsch Med Wschr 1996, 21:679-685 (in German).
23. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al.: Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999, 20:1342-1354.
24. Seggewiss H, Faber L, Strick S, et al.: Ongoing clinical and non-invasive improvement after percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM) [abstract]. Circulation 1998, 98(suppl I):506.
25. Knight C, Kurbaan AS, Seggewiss H, et al.: Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997, 95:2075-2081.
26. Lakkis N, Kleiman N, Killip D, et al.: Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol 1997, 20:417-418.
27. Bhargava B, Agarval R, Kaul U, et al.: Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cradiomyopathy. Cathet Cardiovasc Diagn 1997, 41:56-58.
28. Kornacewicz-Jach Z, Gil R, Wojtarowicz A, et al.: Early results of alcohol ablation of the septal branch of coronary artery in patients with hypertrophic obstructive cardiomyopathy [Polish]. Kardiol Pol 1998, 48:105-112.
29. Nagueh SF, Lakkis NM, He Z-X, et al.: Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998, 32:225-229.
30. Seggewiss H, Faber L, Ziemssen P, et al.: Age related acute results in percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2000, 35(suppl A):188A.
31. Seggewiss H, Faber L, Ziemssen P, Meyners W: Non-surgical septal ablation (PTSMA) in patients with NYHA class IV and hypertrophic obstructive cardiomyopathy (HOCM) [abstract]. Circulation 1999, 100(suppl I):515.
32. Kuhn H, Gietzen F, Leuner CH, et al.: Transcoronary ablation of septal hypertrophy: a new treatment for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000, 89(suppl 4):41-54.
33. Seggewiss H, Faber L: Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr 2001, in press.
34. Kurbaan AS, Seggewiss H, Henein MY, et al.: Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: long-term follow-up of the early patients [abstract]. Circulation 1997, 96(suppl):463.
35. Seggewiss H, Faber L, Gleichmann U: Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg. 1999, 47:94-100.
36. Faber L, Meissner A, Ziemssen P, Seggewiss H: Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000, 83:326-331.
37. Ziemssen P, Faber L, Schlichting J, et al.: Percutaneous septal ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity [abstract]. J Am Coll Cardiol 2000, 35:182A.
38. Curtius JM, Stoecker J, Loesse B, et al.: Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 1989, 76:255-263.